Cardiovascular Disease

Cardiovascular·MeSH: Cardiovascular Diseases

Prevalence

8121.9 / 100K

Incidence

682.0 / 100K/yr

39 drugs in development·21 companies·17 clinical trials

Drug Pipeline by Phase

Approved(9)

Phase 3(14)

Drug	Company
[14c]azd0780	ASTRAZENECA PLC (AZN)
[14c]azd0780 solution for infusion	ASTRAZENECA PLC (AZN)
akcea-apo-lrx	AKCEA THERAPEUTICS, INC. (AKCA)
AZD0780	ASTRAZENECA PLC (AZN)
inclisiran sodium 300 mg in	Novartis AG (NVS)
inclisiran sodium 300 mg in	Novartis AG (NVS)
lepodisiran	ELI LILLY & Co (LLY)
Lepodisiran Sodium	ELI LILLY & Co (LLY)
Olpasiran	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
pelacarsen	Novartis AG (NVS)
Standard Medical Therapy	Merus N.V. (MRUS)
tqj230	Novartis AG (NVS)
tqj230	Novartis AG (NVS)
Zerlasiran	Silence Therapeutics Plc (SLN)

Phase 2(5)

Drug	Company
evolocumab	Novo Nordisk A/S (NVO)
nnc0385-0434 a	Novo Nordisk A/S (NVO)
olpasiran	AMGEN INC (AMGN)
sln360	Silence Therapeutics Plc (SLN)
vtx3232	Ventyx Biosciences, Inc. (VTYX)

Phase 1(1)

Drug	Company
CTX320	CRISPR Therapeutics AG (CRSP)

Preclinical(2)

Drug	Company
non-complement cardiovascular target candidate	RA PHARMACEUTICALS, INC. (RARX)
testing services for clinical trials	INTERLEUKIN GENETICS INC (ILIU)

Unknown(5)

Drug	Company
alirocumab	Sanofi (SNY)
alirocumab	Sanofi (SNYNF)
HeartRisk™	Cardio Diagnostics Holdings Inc. (CDIO)
inclisiran	Sanofi (SNY)
inclisiran	Sanofi (SNYNF)

Phase 1/Phase 2(2)

Drug	Company
CTX321	CRISPR Therapeutics AG (CRSP)
tb-500	IO Biotech, Inc. (IOBT)

Phase 4(1)

Drug	Company
Atozet 10/40 mg or 10/80 mg	Organon & Co. (OGN)

BioSniper tracks 39 drugs in development for Cardiovascular Disease across 21 companies.

There are 17 clinical trials targeting Cardiovascular Disease tracked by BioSniper.

The estimated prevalence of Cardiovascular Disease is approximately 8121.9 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.